

Raffaele Giusti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9380264/publications.pdf>

Version: 2024-02-01

93
papers

3,436
citations

236925

25
h-index

189892

50
g-index

101
all docs

101
docs citations

101
times ranked

5382
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
2	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	7.1	50
3	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	17.0	5
4	Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. <i>ESMO Open</i> , 2022, 7, 100406.	4.5	31
5	EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature. <i>Translational Lung Cancer Research</i> , 2022, 11, 497-503.	2.8	2
6	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <i>PD-L1</i> $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	1.9	7
7	Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1237-1245.	1.9	4
8	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	10.7	50
9	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176.	4.4	11
10	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
11	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	1.2	42
12	Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103271.	4.4	1
13	Smoking status during first-line immunotherapy and chemotherapy in <i>NSCLC</i> patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	1.9	30
14	Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?. <i>Pharmacoeconomics - Open</i> , 2021, 5, 285-298.	1.8	31
15	Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for <i>NSCLC</i> . <i>Cancer Reports</i> , 2021, 4, e1368.	1.4	14
16	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
17	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for <i>PD-L1</i> $\geq 50\%$ advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100078.	4.5	35
18	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17

#	ARTICLE	IF	CITATIONS
19	Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report. <i>Translational Lung Cancer Research</i> , 2021, 10, 2298-2305.	2.8	0
20	Post-progression outcomes of NSCLC patients with PD-L1 expression \geq 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	2.8	19
21	Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel. <i>Advances in Therapy</i> , 2021, 38, 3589-3621.	2.9	19
22	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	2.8	24
23	What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. <i>Cancer Management and Research</i> , 2021, Volume 13, 5203-5210.	1.9	2
24	Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. <i>Supportive Care in Cancer</i> , 2021, 29, 7845-7854.	2.2	7
25	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	4.4	14
26	Response to Reddy et al.: Rapid Transition to Virtual Care during the COVID-19 Epidemic: Experience of a Supportive Care Clinic at a Tertiary Care Cancer Center (DOI. 10.1089/jpm.2020.0737). <i>Journal of Palliative Medicine</i> , 2021, 24, 1128-1129.	1.1	0
27	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	10.7	73
28	My mission is possible: discussing ethical concerns about genomics and precision medicine. <i>Recenti Progressi in Medicina</i> , 2021, 112, 416-418.	0.8	0
29	Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058.	2.2	0
30	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. <i>Clinical and Translational Oncology</i> , 2020, 22, 844-851.	2.4	21
31	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
32	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. <i>Annals of Oncology</i> , 2020, 31, 1746-1754.	1.2	140
33	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \geq 50%: a multicenter study with external validation. , 2020, 8, e001403.		57
34	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , 2020, 10, 588862.	2.8	8
35	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	3.2	14
36	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13

#	ARTICLE	IF	CITATIONS
37	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13
38	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
39	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	4.4	38
40	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
41	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
42	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
43	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologistsâ€™ perspective. <i>ESMO Open</i> , 2020, 5, e000759.	4.5	161
44	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
45	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	4.8	30
46	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020, 9, 1710389.	4.6	9
47	Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. <i>Journal of Translational Medicine</i> , 2020, 18, 49.	4.4	114
48	Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification. <i>Annals of Oncology</i> , 2020, 31, 440-441.	1.2	4
49	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
50	Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatmentâ€™. <i>ESMO Open</i> , 2020, 5, e000933.	4.5	7
51	Cancer Care After Natural Disaster: Different Countries, Similar Problems. <i>Journal of Global Oncology</i> , 2019, 5, 1-2.	0.5	7
52	Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physiciansâ€™ practice. <i>Supportive Care in Cancer</i> , 2019, 27, 3531-3535.	2.2	3
53	Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know. <i>Tumori</i> , 2019, 105, NP48-NP51.	1.1	8
54	What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1439-1444.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	3.7	131
56	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
57	The point of pain in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 51-59.	4.4	30
58	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99.	4.4	52
59	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	2.6	118
60	Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study. <i>Annals of Oncology</i> , 2019, 30, xi20.	1.2	5
61	Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2019, 30, 201-204.	1.4	2
62	The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy. <i>Alcohol and Alcoholism</i> , 2019, 54, 47-50.	1.6	4
63	CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20628-e20628.	1.6	4
64	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2559-2559.	1.6	0
65	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 353-361.	2.4	3
66	Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, e17-e20.	3.4	10
67	The use of fentanyl in pain management in head and neck cancer patients: a narrative review. <i>British Journal of Pain</i> , 2018, 12, 155-162.	1.5	9
68	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018, 3, e000389.	4.5	4
69	Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. <i>ESMO Open</i> , 2018, 3, e000345.	4.5	23
70	Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2018, 29, iv166-iv191.	1.2	461
71	Re. "Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey" Nutrition, 2017, 39-40, 96-97.	2.4	1
72	Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law. <i>Pain Medicine</i> , 2017, 18, 1822-1824.	1.9	3

#	ARTICLE	IF	CITATIONS
73	Caring for Cancer Patients After the Italian Earthquakes: A Proposal From the Field. <i>Disaster Medicine and Public Health Preparedness</i> , 2017, 11, 4-6.	1.3	1
74	Complete Tumor Response with Afatinib 20Âmg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Clinical Drug Investigation</i> , 2017, 37, 581-585.	2.2	2
75	Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). <i>Advances in Therapy</i> , 2017, 34, 120-135.	2.9	19
76	Integration between Oncology and Palliative Care: A Plan for the Next Decade?. <i>Tumori</i> , 2017, 103, e23-e23.	1.1	0
77	Incidence of alcoholism among cancer patients undergoing active treatment. <i>Annals of Oncology</i> , 2017, 28, vi85.	1.2	0
78	Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a web based online survey among Italian experts on supportive care in cancer. <i>Annals of Oncology</i> , 2017, 28, vi103.	1.2	0
79	Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program. <i>Annals of Oncology</i> , 2017, 28, ii38.	1.2	0
80	Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. <i>Anticancer Research</i> , 2017, 37, 2633-2639.	1.1	7
81	Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 712-719.	2.8	9
82	Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.3	7
83	Toxicity profile of afatinib in advanced EGFR mutated NSCLC treatment: a real world single-center experience. <i>Annals of Oncology</i> , 2016, 27, iv14.	1.2	0
84	Immigrants Accessing End-of-Life Care in Italy: The Tuscany Tumor Association Experience. <i>Journal of Pain and Symptom Management</i> , 2016, 51, e7.	1.2	1
85	Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 273-280.	1.3	4
86	Comment on "What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion". <i>Drugs</i> , 2016, 76, 1059-1061.	10.9	1
87	Integration between oncology and palliative care: does one size fit all?. <i>Annals of Oncology</i> , 2016, 27, 549.	1.2	7
88	Is it possible to teach pain therapy playing basketball?. <i>Annals of Palliative Medicine</i> , 2016, 5, 71-3.	1.2	0
89	Sequential strategy with ALK-TKIs for ALK-positive advanced NSCLC: results of a multicenter analysis. <i>Annals of Oncology</i> , 2015, 26, vi75.	1.2	1
90	Genetic polymorphism can help physician choosing the best lung cancer chemotherapy. <i>Annals of Oncology</i> , 2015, 26, vi85.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015, 90, 255-260.	2.0	43
92	Multidisciplinary approach to fetal adenocarcinoma of the lung: A case report. <i>Thoracic Cancer</i> , 2014, 5, 97-100.	1.9	2
93	Rapid Resolution of Refractory Chemotherapy-Induced Oral Mucositis With Platelet Gel-Released Supernatant in a Pediatric Cancer Patient: A Case Report. <i>Journal of Pain and Symptom Management</i> , 2014, 48, e2-e4.	1.2	7